913
Views
2
CrossRef citations to date
0
Altmetric
Review

Diagnostic challenges in rapidly progressive dementia

&
Pages 761-772 | Received 19 Jul 2018, Accepted 30 Aug 2018, Published online: 17 Sep 2018

References

  • Geschwind MD, Haman A, Miller BL. Rapidly progressive dementia. Neurol Clin. 2007;25:783–807.
  • Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132:2659–2668.
  • Soto ME, Andrieu S, Arbus C, et al. Rapid cognitive decline in Alzheimer’s disease. Consensus paper. J Nutr Health Aging. 2008;12(10):703–713.
  • Schmidt C, Wolff M, Weitz M, et al. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68(9):1124–1130.
  • Gaig C, Valldeoriola F, Gelpi E, et al. Rapidly progressive diffuse Lewy body disease. Mov Disord. 2011;26(7):1316–1323.
  • Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Reviews Neurosci. 2010;11(3):155–159.
  • Poser S, Mollenhauer B, Kraubeta A, et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain. 1999;122(12):2345–2351.
  • Geschwind MD, Shu H, Haman A, et al. Rapidly progressive dementia. Ann Neurol. 2008;64(1):97–108.
  • Chitravas N, Jung RS, Kofskey DM, et al. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol. 2011;70(3):437–444.
  • Grau-Rivera O, Gelpi E, Nos C, et al. Clinicopathological correlations and concomitant pathologies in rapidly progressive dementia: a brain bank series. Neurodegener Dis. 2015;15(6):350–360.
  • Geschwind MD. Rapidly progressive dementia. Continuum (Minneap Minn). 2016;22(2):510–537.
  • Hermann P, Laux M, Glatzel M, et al. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology. 2018;91(4):e331–e338.
  • Stoeck K, Sanchez-Juan P, Gawinecka J, et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain. 2012;135(10):3051–3061.
  • Studart Neto A, Soares Neto HR, Simabukuro MM, et al. Rapidly progressive dementia: prevalence and causes in a neurologic unit of a tertiary hospital in Brazil. Alzheimer Dis Assoc Disord. 2017;31(3):239–243.
  • Anuja P, Venugopalan V, Darakhshan N, et al. Rapidly progressive dementia: an eight year (2008–2016) retrospective study. PLoS One. 2018 cited 2018 Jul 5;13. DOI:10.1371/journal.pone.0189832.
  • Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136–144.
  • Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64:1586–1591.
  • Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob-disease. Brain. 2006;129:2278–2287.
  • Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011;17:175–178.
  • McGuire LI, Peden AH, Orru CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2012;72:278–285.
  • Cramm M, Schmitz M, Karch A, et al. Stability and reproducibility underscore utility of RT-QuIC for diagnosis of Creutzfeldt-Jakob disease. Mol Neurobiol. 2016;53(3):1896–1904.
  • Bongianni M, Orrù C, Groveman BR, et al. Diagnosis of human prion disease using real-time quaking-induced conversion testing of olfactory mucosa and cerebrospinal fluid samples. JAMA Neurol. 2017;74(2):155–162.
  • Hayashi Y, Iwasaki Y, Yoshikura N, et al. An autopsy-verified case of steroid-responsive encephalopathy with convulsion and a false-positive result from the real-time quaking-induced conversion assay. Prion. 2017;11:284–292.
  • Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76:1711–1719.
  • Fragoso DC, Gonçalves Filho AL, Pacheco FT, et al. Imaging of Creutzfeldt-Jakob disease: imaging patterns and their differential diagnosis. Radiographics. 2017;37(1):234–257.
  • Gaudino S, Gangemi E, Colantonio R, et al. Neuroradiology of human prion diseases, diagnosis and differential diagnosis. Radiol Med. 2017;122(5):369–385.
  • Heath CA, Cooper SA, Murray K, et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol. 2010;67:761–770.
  • WHO. Global Surveillance, diagnosis, and Therapy of Human Transmissible spongiform Encephalopathies: Report of WHO consultation, February 9–11, 1998. Geneva, Switzerland.
  • Varges D, Manthey H, Heinemann U, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry. 2017;88(2):119–125.
  • Schmidt C, Redyk K, Meissner B, et al. Clinical features of rapidly progressive Alzheimer’s disease. Dement Geriatr Cogn Disord. 2010;29:371–378.
  • Josephs KA, Ahlskog JE, Parisi JE, et al. Rapidly progressive neurodegenerative dementias. Arch Neurol. 2009;66:201–207.
  • Schmidt C, Haïk S, Satoh K, et al. Rapidly progressive Alzheimer’s disease: a multicenter update. J Alzheimers Dis. 2012;30(4):751–756.
  • Abu-Rumeileh S, Capellari S, Parchi P. Rapidly progressive Alzheimer’s disease: contributions to clinical-pathological definition and diagnosis. J Alzheimers Dis. 2018;63(3):887–897.
  • Hecht M, Krämer LM, von Arnim CAF, et al. Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathol. 2018;135(5):681–694.
  • Cohen ML, Kim C, Haldiman T, et al. Rapidly progressive Alzheimer’s disease features distinct structures of amyloid-β. Brain. 2015;138(4):1009–1022.
  • Qiang W, Yau WM, Lu JX, et al. Structural variation in amyloid-β fibrils from Alzheimer’s disease clinical subtypes. Nature. 2017;541(7636):217–221.
  • Drummond E, Nayak S, Faustin A, et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease. Acta Neuropathol. 2017;133(6):933–954.
  • Ba M, Li X, Ng KP, et al. The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer’s disease from the Alzheimer’s disease neuroimaging initiative database. Alzheimers Dement. 2017;3(1):107–113.
  • McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269.
  • Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018 Apr;14(4):535–562.
  • Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer’s disease therapy and prevention strategies. Annu Rev Med. 2017;68:413–430.
  • National Institute for Clinical Excellence (NICE). Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease. NICE Technology Appraisal Guidance 217 (Review of NICE Technology Appraisal Guidance 111). National Institute for Clinical Excellence. 2011.
  • Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203–212.
  • McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurol. 2017;89(1):88–100.
  • Tartaglia MC, Johnson DY, Thai JN, et al. Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease. Can J Neurol Sci. 2012;39:304–310.
  • Graff-Radford J, Aakre J, Savica R, et al. Duration and pathologic correlates of Lewy body disease. JAMA Neurol. 2017;74(3):310–315.
  • Garcia-Esparcia P, López-González I, Grau-Rivera O, et al. Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. Front Neurol. 2017;8:89.
  • Llorens F, Schmitz M, Varges D, et al. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol. 2016;263(11):2271–2277.
  • Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812–818.
  • Shahnawaz M, Tokuda T, Waragai M, et al. Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 2017;74(2):163–172.
  • Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;3:CD006504.
  • Mori E, Ikeda M, Kosaka K, et al. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72:41–52.
  • Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo controlled trial. Lancet Neurol. 2010;9:969–977.
  • Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164:1491–1498.
  • Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in Parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153–156.
  • McCann H, Stevens CH, Cartwright H, et al. α-Synucleinopathy phenotypes. Parkinsonism Relat Disord. 2014;20(Suppl 1):S62–7.
  • Bjornsdottir A, Gudmundsson G, Blondal H, et al. Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry. 2013;84(2):136–140.
  • Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–676.
  • Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy: a position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Mov Disord. 2014;29:857–867.
  • Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy: a review of the MSA biomarker initiative. Neurobiol Dis. 2015;80:29–41.
  • Papageorgiou SG, Kontaxis T, Bonakis A, et al. Rapidly progressive dementia: causes found in a Greek tertiary referral center in Athens. Alzheimer Dis Assoc Disord. 2009;23:337–346.
  • Taniguchi-Watanabe S, Arai T, Kametani F, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131(2):267–280.
  • Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017;140(12):3329–3345.
  • Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130:2616–2635.
  • Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327–340.
  • Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–864.
  • Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197–2204.
  • Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–629.
  • O’Brian JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–1706.
  • Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology. 1993;43:250–260.
  • Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci. 2013;5:17.
  • Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the vascular impairment of cognition classification consensus study. Alzheimers Dement. 2018;14(3):280–292.
  • Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease - systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–352.
  • Hermann P, Romero C, Schmidt C, et al. CSF biomarkers and neuropsychological profiles in patients with cerebral small-vessel disease. PLoS One. 2014 [cited 2018 Jul 5];7. DOI:10.1371/journal.pone.0105000
  • Skillbäck T, Delsing L, Synnergren J, et al. CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol Aging. 2017;59:1–9.
  • Sjögren M, Blomberg M, Jonsson M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001;66(3):510–516.
  • Zerr I, Schmitz M, Karch A, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018;14(6):751–763.
  • Bjerke M, Zetterberg H, Edman A, et al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis. 2011;27(3):665–676.
  • Wallin A, Kapaki E, Boban M, et al. Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report. BMC Neurol. 2017;17(1):102.
  • Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782–792.
  • Gao B, Lyu C, Lerner A, et al. Controversy of posterior reversible encephalopathy syndrome: What have we learnt in the last 20 years? J Neurol Neurosurg Psychiatry. 2018;89(1):14–20.
  • Vilela P. Acute stroke differential diagnosis: stroke mimics. Eur J Radiol. 2017;96:133–144.
  • Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol. 2007;262:442–451.
  • Salvarani C, Brown RD Jr, Christianson TJ, et al. Adult primary central nervous system vasculitis treatment and course: analysis of one hundred sixty-three patients. Arthritis Rheumatol. 2015;67(6):1637–1645.
  • Salvarani C, Brown RD Jr, Hunder GG. Adult primary central nervous system vasculitis. Lancet. 2012;9843:767–777.
  • Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine. 1988;67:20–39.
  • Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10:835–844.
  • Lancaster E, Dalmau J. Neuronal autoantigens—pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8(7):380–390.
  • Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840–851.
  • Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology. 2015;85:235–239.
  • Graus F, Escudero D, Oleaga L, et al. Syndrome and outcome of antibody-negative limbic encephalitis. Eur J Neurol. 2018 [cited 2018 Jul 5];6. DOI:10.1111/ene.13661
  • Afshari M, Afshari ZS, Schuele SU. Pearls & oysters: hashimoto encephalopathy. Neurology. 2012;29;78(22):134–137.
  • Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–1098.
  • Prüss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology. 2010;75:1735–1739.
  • Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
  • Tüzün E, Zhou L, Baehring JM, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118:737–743.
  • Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655–1667.
  • Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165.
  • Alford K, Vera JH. Cognitive impairment in people living with HIV in the ART era: a review. Br Med Bull. 2018 cited 2018 Jul 5;14. DOI:10.1093/bmb/ldy019.
  • Compain C, Sacre K, Puéchal X, et al. Central nervous systeminvolvement in Whipple disease: clinical study of 18patients and long-term follow-up. Medicine. 2013;92(6):324–330.
  • Rosenbloom MH, Atri A. The evaluation of rapidly progressive dementia. Neurologist. 2011;17(2):67–74.
  • Appleby BS, Lyketsos CG. Rapidly progressive dementias and the treatment of human prion diseases. Expert Opin Pharmacother. 2011;12:1–12.
  • Mahajan S, Appleby BS. Comprehensive and methodical: diagnostic and management approaches to rapidly progressive dementia. Curr Treat Options Neurol. 2017;19(11):40.
  • Van der Meulen M, Dirven L, Habets EJJ, et al. Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. Lancet Oncol. 2018;19(8):e407–e418.
  • Chinnery PF. Mitochondrial disorders overview. In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews® [Internet]. [Updated 2000 Jun 8; Updated 2014 Aug 14]. Seattle (WA): University of Washington, Seattle; 1993–2018.
  • Zhang Y, Gao T, Tao QQ. Spectrum of noncerebrovascular rapidly progressive cognitive deterioration: a 2-year retrospective study. Clin Interv Aging. 2017;12:1655–1659.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.